Aligos Therapeutics and Metrion explore key approaches to cardiovascular safety screening in drug discovery.
Dr Chris Mathes, CCO, and Dr Sophie Rose, Head of Business Development Europe, explain why companies choose Metrion as their preferred pre-clinical CRO.
Aligos Therapeutics and Metrion explore key approaches to cardiovascular safety screening in drug discovery.
Academic case study on Nav1.9 as a drug target by Associate Professor David Bulmer (University of Cambridge). Overview of Metrion’s newly developed Nav1.9 screening assays by Metrion CSO, Dr. Eddy Stevens.